http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정부의 '약가제도 개편 및 혁신형 제약기업 지원' 정책의 효과성 연구
신광수,박교준,박하영 한국보건경제정책학회 2020 보건경제와 정책연구 Vol.26 No.1
The Korean government implemented a policy in 2012 to bring structural changes to the pharmaceutical industry whose dependence on generic drugs was high and innovation capacity to develop new drugs was low. The policy was comprised of two parts, price reduction of generic drugs and supports of selected innovative pharmaceutical firms with tax credits, higher drug prices, and various managerial benefits. The objective of this study was to assess the impacts of the policy by examining firm level responses in internal research and development (R&D) investment and effort to acquire external R&D resources through strategic alliances and merger and acquisitions (M&As). The study also examined innovation outputs (numbers of patent registration and clinical trials) which are results of R&D inputs and the final financial outcome (revenue). The study collected data for 46 publicly listed firms on the KOSPI and KOSDAQ markets during 2009-2016, 20 selected innovative firms and 26 non-selection firms, and compared the study variables of the two groups to estimate the impacts with differences-in-differences (DD) and panel regression DD with control variables. Results indicated that selected innovative firms were superior to their couterpart firms in R&D inputs, innovation outputs, and financial outcome in the first place, and the government supports strengthened their superiority in internal R&D investments, alliances and M&As, and patent registration. However, the policy did not have any influence on the number of clinical trials and revenue, and the reduction of drug prices did not have statistically significant impacts on the study variables either. The study contributed in providing policy makers and firm managers with directions for the advancement of the Korean pharmaceutical industry despite the limitation of short data period and the generalizability problem.
비과적 질환으로 내원한 환자에서 비부비동 증상과 심리적 증상에 대한 분석
신광수,조석현,안태환,정진혁,김경래,정승아,김석현 대한이비인후과학회 2009 대한이비인후과학회지 두경부외과학 Vol.52 No.10
Background and Objectives Quality of life is one of the important issues in the treatment of patients with chronic diseases of the nose and sinuses. Psychological disturbance may affect patient’s symptoms and the outcome after treatments. In this study, we aimed to evaluate both sinonasal and psychological profiles in rhinologic patients. Subjects and Method From February 2007 to January 2008, 117 rhinologic patients who had been scheduled for the nasal and sinus surgery were enrolled. They were divided into two groups, nasal cavity disease (NCD, n=53) and chronic rhinosinusitis (CRS, n=64). Somatic and psychological symptoms were evaluated using the Sinonasal Outcome Test-20 (SNOT-20) and Symptom Checklist-90-Revised (SCL-90-R). All of the patients underwent nasal endoscopy, computed tomography, acoustic rhinometry, T&T olfactometry and allergic skin prick test. Results Global severity index of the SCL-90-R was within the normal range for all the rhinologic patients. There was no difference of SNOT-20 (p=0.220) and SCL-90-R (p=0.367) scores between the two groups. In the non-allergic patients, the CRS group had higher scores of SNOT- 20 (p=0.002) and SCL-90-R (p=0.003) compared to the NCD group. The allergic NCD patients showed significantly higher scores of SNOT-20 (p=0.020) and SCL-90-R (p=0.003) compared to non-allergic NCD patients. Conclusion Allergy could augment the patient’s somatic and psychological symptoms, especially in the NCD group. Therefore, allergy control may be important in the management of patients with nasal cavity diseases if they have allergic rhinitis.